The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Showing 1-20 of 182 articles
Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations
Lunardi M,
Louvard Y,
Lefèvre T,
Stankovic G,
Burzotta F,
Kassab G,
Lassen J,
Darremont O,
Garg S,
Koo B,
Holm N,
Johnson TW,
Pan M,
Chatzizisis YS,
Banning AP,
Chieffo A,
Dudek D,
Hildick-Smith D,
Garot J,
Henry T,
Dangas G,
Stone G,
Krucoff M,
Cutlip D,
Mehran R,
Wijns W,
Sharif F,
Serruys P,
Onuma Y
May 18, 2022 | 10.4244/EIJ-E-22-00018
Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial
van Geuns R,
Chun-Chin C,
McEntegart M,
Merkulov E,
Kretov E,
Lesiak M,
O’Kane P,
Hanratty C,
Bressollette E,
Silvestri M,
Wlodarczak A,
Barragan P,
Anderson R,
Protopopov A,
Peace A,
Menown I,
Rocchiccioli P,
Onuma Y,
Oldroyd K
April 22, 2022 | 10.4244/EIJ-D-21-00514
A comparison of risk prediction models for patients with acute coronary syndromes
March 18, 2022 | 10.4244/EIJ-D-21-00536
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial
de Winter R,
Zaman A,
Hara H,
Gao C,
Ono M,
Garg S,
Smits P,
Tonino P,
Hofma S,
Moreno R,
Choudhury A,
Petrov I,
Cequier A,
Colombo A,
Kaul U,
Onuma Y,
Serruys P
March 15, 2022 | 10.4244/EIJ-D-21-00766
Reply: Composite endpoints in clinical trials - simplicity or perfection?
January 28, 2022 | 10.4244/EIJ-D-21-00440R
Optimal dual antiplatelet therapy duration for bioresorbable scaffolds: an individual patient data pooled analysis of the ABSORB trials
Azzalini L,
Ellis S,
Kereiakes D,
Kimura T,
Gao R,
Onuma Y,
Chevalier B,
Dressler O,
Crowley A,
Zhou Z,
Redfors B,
Serruys P,
Stone G
December 17, 2021 | 10.4244/EIJ-D-21-00263
Age and functional relevance of coronary stenosis: a post hoc analysis of the ADVISE II trial
Faria D,
Lee JM,
van de Hoef T,
Mejía-Rentería H,
Echavarria-Pinto M,
Baptista S,
Cerrato E,
Garcia-Garcia H,
Davies J,
Onuma Y,
Samady H,
Piek J,
Serruys P,
Lerman A,
Escaned J
October 20, 2021 | 10.4244/EIJ-D-20-01163
Statistical methods for composite endpoints
Hara H,
van Klaveren D,
Kogame N,
Chichareon P,
Modolo R,
Tomaniak M,
Ono M,
Kawashima H,
Takahashi K,
Capodanno D,
Onuma Y,
Serruys P
April 2, 2021 | 10.4244/EIJ-D-19-00953
Online three-dimensional OFDI-guided versus angiography-guided PCI in bifurcation lesions: design and rationale of the randomised OPTIMUM trial
Miyazaki Y,
Muramatsu T,
Asano T,
Katagiri Y,
Sotomi Y,
Nakatani S,
Takahashi K,
Kogame N,
Higuchi Y,
Ishikawa M,
Kyono H,
Yano M,
Ozaki Y,
Serruys P,
Okamura T,
Onuma Y
March 19, 2021 | 10.4244/EIJ-D-18-00902
Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study
Milewski K,
Takahashi K,
Asano T,
Katagiri Y,
Hochul M,
Buszman P,
Tomaniak M,
Gorycki B,
Zurakowski A,
Janas A,
Mlodziankowski A,
Kachel M,
Wykrzykowska J,
Wijns W,
de Winter R,
Buszman P,
Onuma Y,
Serruys P
February 19, 2021 | 10.4244/EIJ-D-18-01201
Coronary interventions in 2020: the year in review
February 5, 2021 | 10.4244/EIJ-D-20-01343
A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial
Hara H,
Gao C,
Kogame N,
Ono M,
Kawashima H,
Wang R,
Morel M,
O'Leary N,
Sharif F,
Möllmann H,
Reiber J,
Sabaté M,
Zaman A,
Wijns W,
Onuma Y,
Serruys P
December 18, 2020 | 10.4244/EIJ-D-20-00772
Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial
Onuma Y,
Chevalier B,
Ono M,
Cequier A,
Dudek D,
Haude M,
Carrié D,
Sabaté M,
Windecker S,
Rapoza R,
West N,
Reith S,
de Sousa Almeida M,
Campo G,
Iniguez-Romo A,
Serruys P
December 4, 2020 | 10.4244/EIJ-D-20-00024
Valvular heart interventions: advances from 2019 to 2020
November 20, 2020 | 10.4244/EIJ-D-20-00096
Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial
Takahashi K,
Chichareon P,
Modolo R,
Kogame N,
Chang C,
Tomaniak M,
Moschovitis A,
Curzen N,
Haude M,
Jung W,
Holmvang L,
Garg S,
Tijssen J,
Wykrzykowska J,
de Winter R,
Hamm C,
Steg P,
Stoll H,
Onuma Y,
Valgimigli M,
Vranckx P,
Windecker S,
Serruys P
October 23, 2020 | 10.4244/EIJ-D-19-00498
Latest news
NEW ISSUE
A TAVI in Bicuspid Anatomies; TMVI; Bailout-TEER or Medical Therapy; DRT following LAAO; Cost-Effectiveness of FFR-Guided MVD Revascularisation in STEMI and more
June 24, 2022
AHEAD OF PRINT
Bioprosthetic dysfunction of the LOTUS valve
FREE ARTICLE - Rutger-Jan Nuis et al
June 17, 2022
AHEAD OF PRINT
Coronary access after ViV-TAVI with ACURATE neo2
FREE ARTICLE - Arif A. Khokhar et al.
June 16, 2022
AHEAD OF PRINT
Prognostic value of structural and functional microvascular dysfunction
FREE ARTICLE - Coen K.M. Boerhout et al
June 13, 2022
AHEAD OF PRINT
TAVR with the ACURATE neo2
FREE ARTICLE - Andrea Scotti et al
June 8, 2022
AHEAD OF PRINT
Antithrombotic strategy selection using smartphone technology
FREE ARTICLE - Jaya Chandrasekhar et al
June 3, 2022
AHEAD OF PRINT
The fingerprints of plaque rupture healing as detected by serial OCT imaging
FREE ARTICLE - Rocco Vergallo et al
June 2, 2022